Skip to content

PARP Inhibitor Maintenance Therapy and What Survival Numbers Really Mean

A treatment that delays ovarian cancer progression does not automatically help patients live longer. That distinction matters when deciding whether to take a PARP inhibitor after chemotherapy.

Progression-free survival measures time before cancer worsens or a patient dies. Overall survival measures time until death from any cause. Both provide useful information, but they answer different questions.

PARP inhibitor maintenance can provide substantial benefits for appropriately selected patients. Understanding those benefits requires looking at the specific drug, tumor biomarkers, treatment setting, survival findings and side effects together.

A statement such as “70% lower risk of progression” cannot answer all of those questions.

Should Your Cancer Have Been Found Sooner?

Contact us today for a free consultation.

How PARP Inhibitor Maintenance Works

PARP stands for poly(ADP-ribose) polymerase, a group of proteins involved in repairing damaged DNA. PARP inhibitors interfere with that repair process, which can make it harder for certain cancer cells to survive.

The National Cancer Institute’s ovarian cancer treatment guide identifies these drugs as targeted therapies used in selected ovarian, fallopian tube and primary peritoneal cancers.

Maintenance treatment is given after an initial treatment response to help maintain disease control. It does not necessarily mean that all cancer has disappeared, and it is not the same as prescribing a drug to treat cancer that is actively progressing after several previous treatments.

That difference becomes important when interpreting trial results and changes to FDA-approved uses.

Progression-Free Survival and Overall Survival Measure Different Outcomes

The FDA’s guidance on cancer clinical trial endpoints distinguishes these measurements by the event being counted and the time from which it is measured.

Measurement

What it measures in a randomized trial

What it cannot establish by itself

Progression-free survival, or PFS

Time from randomization until objectively defined cancer progression or death, whichever occurs first

Whether patients live longer overall or feel better during treatment

Overall survival, or OS

Time from randomization until death from any cause

Whether treatment improved symptoms or quality of life

Patient-reported quality of life

Patients’ reports of symptoms, functioning and treatment burden

Whether treatment extends life

Progression is assessed according to the trial’s defined criteria, often using imaging. PFS therefore does not simply mean “time without symptoms” or “time without cancer.”

Overall survival includes deaths from any cause. It can require longer follow-up, and interpretation can be affected by treatments patients receive after progression.

The FDA recognizes that PFS can support approval in appropriate circumstances. Its role depends on the disease, treatment setting, effect size and overall benefit-risk assessment. It is not universally a substitute for proven longer survival. fda.gov

What a “70% Lower Risk” Actually Means

Cancer studies often report a hazard ratio, abbreviated HR. It compares the rate at which an event occurs in one group with the rate in another over follow-up.

For PFS, the event is progression or death. For OS, it is death.

A PFS hazard ratio of 0.30 is commonly described as a 70% reduction in the hazard of progression or death. It does not mean:

  • Patients live 70% longer.

  • Seventy percent of patients are cured.

  • Each patient’s chance of recurrence falls by 70 percentage points.

  • The treatment reduces the risk of death by 70%.

Those are different claims requiring different evidence.

Absolute results help explain the practical size of a benefit. Ask how many patients remained progression-free at a stated time, what the comparison group experienced and whether survival was also measured.

Median Survival Is Not an Individual Forecast

Median survival is the point at which the estimated survival curve reaches 50%.

A median PFS of 24 months does not mean treatment stops working for everyone at two years. Some patients progress earlier; others remain progression-free longer.

Likewise, subtracting the median survival of two trial groups does not tell an individual patient how many additional months the drug will provide.

Statistical Significance Requires Context

A confidence interval describes the uncertainty around an estimate. For a hazard ratio, an interval crossing 1.0 generally means the analysis has not excluded no difference at that confidence level.

But a confidence interval alone is not the complete statistical plan. Trials can have stricter, prespecified significance thresholds because they test multiple outcomes or analyze results repeatedly.

SOLO1 illustrates why that detail matters.

What Major PARP Inhibitor Trials Show

PARP inhibitor studies should be read within their own populations. A result in newly diagnosed BRCA-mutated cancer cannot automatically be applied to recurrent disease or cancer without the same biomarkers.

SOLO1 Showed Encouraging Seven-Year Survival Findings With an Important Qualification

SOLO1 studied maintenance olaparib after response to first-line platinum chemotherapy in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation.

In the seven-year SOLO1 survival analysis, the estimated proportion alive was 67.0% with olaparib and 46.5% with placebo. The OS hazard ratio was 0.55, with a 95% confidence interval of 0.40 to 0.76.

Those findings favored olaparib. However, this was a prespecified descriptive analysis, and its P value of .0004 did not meet the trial’s stricter prespecified threshold of less than .0001.

The authors described the improvement as clinically meaningful while acknowledging that it was not statistically significant under those criteria.

It should therefore not be presented as a final analysis that definitively proved an overall-survival benefit. It provides important, encouraging survival evidence in a defined patient group. pubmed.ncbi.nlm.nih.gov

PRIMA Has Final Overall-Survival Results

PRIMA studied first-line niraparib maintenance in patients with newly diagnosed advanced ovarian cancer at high risk of recurrence who had responded to platinum chemotherapy.

The final PRIMA overall-survival publication reported median OS of 46.6 months with niraparib and 48.8 months with placebo in the overall population. The hazard ratio was 1.01, with a 95% confidence interval of 0.84 to 1.23.

The trial did not demonstrate an overall-survival improvement, although its progression-free survival benefit persisted.

These findings should no longer be described simply as immature survival data. They also do not establish that the two treatments have exactly identical effects or that every subgroup experiences the same outcome.

Subsequent treatments differed between groups, which is relevant to interpretation. That complication does not justify replacing the observed OS result with an assumed survival benefit. pmc.ncbi.nlm.nih.gov

PAOLA-1 Shows Why Biomarkers and the Comparison Treatment Matter

PAOLA-1 evaluated adding olaparib to bevacizumab maintenance after first-line treatment. The comparison group received bevacizumab plus placebo.

The final PAOLA-1 survival report did not show a statistically significant OS improvement in the overall trial population.

In the HRD-positive population, a prespecified exploratory analysis favored olaparib plus bevacizumab. Estimated five-year survival was 65.5% versus 48.4%, with an OS hazard ratio of 0.62.

This result concerns a biomarker-defined population receiving a particular combination. It cannot establish that olaparib alone produces the same result, or that patients with HRD-negative tumors receive the same benefit. pubmed.ncbi.nlm.nih.gov

Recurrent Disease Requires Its Own Evidence

SOLO2 studied olaparib maintenance in platinum-sensitive relapsed ovarian cancer with a BRCA mutation.

Its final overall-survival analysis reported median OS of 51.7 months with olaparib and 38.8 months with placebo. The hazard ratio was 0.74, and the result did not meet the predefined statistical significance threshold.

The numerical difference favored olaparib, but it should not be described as conclusive proof of longer survival.

First-line maintenance and maintenance after recurrence are separate clinical decisions. Previous PARP inhibitor exposure and other treatment history also matter.

Why Longer PFS May Not Produce Longer Overall Survival

Several factors can separate these outcomes.

Patients initially assigned to a comparison group may receive a PARP inhibitor or another effective therapy after progression. This can reduce the difference in overall survival between the original groups.

Treatment toxicity and the effectiveness of later therapies can also affect outcomes. A study may show that a drug controls cancer for longer without demonstrating that the entire treatment sequence extends life.

Time without progression can still matter to patients. It may postpone another treatment or provide a period of disease control. Whether that time is experienced as a benefit also depends on symptoms, side effects and treatment burden.

A nonsignificant OS result does not make a PFS result meaningless. It limits what can accurately be claimed about longer life.

FDA Changes Must Be Read by Drug and Treatment Setting

Some PARP inhibitor indications for heavily pretreated ovarian cancer were withdrawn following concerns arising from later evidence. These were specific indications, rather than withdrawal of every ovarian cancer use of the drugs.

The FDA’s withdrawal notice for later-line olaparib and niraparib indications documents that distinction. A withdrawn use for treating progressing cancer should not be confused with maintenance after a chemotherapy response.

More recently, the FDA’s 2025 niraparib review concluded that PRIMA’s final survival findings did not support retaining first-line maintenance eligibility for all patients. The indication was narrowed to HRD-positive disease.

The practical question is therefore specific: What evidence and current prescribing information support this drug in my treatment setting?

An older article describing broad eligibility may no longer reflect the current label. A later regulatory change also does not, by itself, prove that an earlier prescription was negligent. accessdata.fda.gov

Why BRCA and HRD Results Matter

BRCA1 and BRCA2 help cells repair damaged DNA. A harmful mutation can impair that repair system. Homologous recombination deficiency, or HRD, describes impaired function of a related DNA-repair pathway and can include tumors with BRCA mutations.

An inherited, or germline, mutation and a mutation found in the tumor are not necessarily the same finding. The distinction can affect both treatment decisions and whether inherited-risk counseling is appropriate.

The olaparib prescribing information distinguishes first-line maintenance for BRCA-mutated advanced disease from olaparib plus bevacizumab maintenance for HRD-positive disease.

The current niraparib prescribing information also identifies biomarker requirements for its approved maintenance uses.

A positive result does not guarantee benefit. It helps determine which evidence applies and whether a particular approved indication fits.

Ask which tests were performed, what they found and how the results changed the recommendation.

Safety Monitoring Is Part of the Treatment Decision

PARP inhibitors can cause fatigue, nausea and reduced blood counts. Anemia can contribute to weakness and breathlessness. Low platelets can increase bleeding risk, and reduced infection-fighting cells can increase susceptibility to infection.

Serious risks include myelodysplastic syndrome and acute myeloid leukemia, both disorders of blood-forming cells. Some reported cases have been fatal.

Risk varies across drugs, populations and previous treatment histories. A percentage from one trial should not be presented as every patient’s risk.

The olaparib safety warnings call for blood counts before treatment and monthly during treatment, with additional evaluation for prolonged abnormalities.

Niraparib has a different monitoring schedule. Its label calls for blood counts weekly during the first month, monthly for the next 11 months and periodically afterward. It also specifies blood-pressure and heart-rate monitoring because hypertension and cardiovascular effects can occur. LYNPARZA- olaparib tablet, film coated

Monitoring can lead to a clinician-directed treatment interruption, dose reduction or further investigation. Those adjustments are part of managing treatment safely.

Report fever, unusual bleeding, worsening breathlessness or other concerning symptoms promptly. Do not change or stop treatment without guidance from your oncology team.

Questions to Ask Before Starting Maintenance

A useful discussion should connect the research to your diagnosis and priorities.

Ask:

  • Which trial population most closely matches me? Clarify whether the evidence concerns first-line treatment, recurrence, BRCA-mutated disease or another HRD-defined group.

  • What benefit was demonstrated? Separate delayed progression, longer overall survival and improved quality of life.

  • How large was the absolute benefit? Ask for results at a stated time alongside any hazard ratio.

  • What are the alternatives? Discuss appropriate maintenance options, observation or a clinical trial where relevant.

  • What monitoring will I need? Confirm who reviews laboratory results and what happens if abnormalities persist.

  • How long is treatment planned? Duration differs by drug, setting and clinical circumstances.

Your priorities may include delaying another chemotherapy course, reducing recurrence risk, preserving daily functioning or limiting treatment burden. Those priorities belong in the decision.

What New York Informed Consent Requires

New York Public Health Law 2805-d addresses disclosure of treatment alternatives and reasonably foreseeable risks and benefits that a reasonable practitioner would disclose under similar circumstances.

The information must permit a knowledgeable evaluation. For a nonemergency treatment decision, that can require more than quoting a favorable progression statistic.

A lack-of-informed-consent claim also requires showing that a reasonably prudent person in the patient’s position would not have undergone treatment if fully informed, and that the lack of informed consent proximately caused the claimed injury.

An incomplete explanation, standing alone, does not establish every element of a claim. The treatment context, available evidence, actual discussion and resulting harm must be examined. NYSenate.gov

When PARP Inhibitor Care May Warrant Legal Review

Potential concerns include inappropriate treatment selection, failure to act on important biomarker information, inadequate monitoring or failure to investigate persistent blood-count abnormalities.

A recognized complication does not automatically establish malpractice. Neither does cancer progression despite treatment.

A review must identify what accepted care required at the time, whether care departed from that standard and whether the departure caused additional injury.

Relevant records serve different purposes:

  • Pathology and biomarker reports help establish the disease and treatment-selection information.

  • Prescribing and oncology notes show the treatment rationale and documented discussion.

  • Blood counts and monitoring records show when abnormalities appeared and how clinicians responded.

  • Hospital and specialist records help assess the injury and its possible causes.

These issues differ from a claim involving a delayed ovarian cancer diagnosis. A treatment-safety claim should be evaluated according to the actual alleged error.

Filing Deadlines Depend on the Claim

Under CPLR 214-a’s medical malpractice limitations rule, the ordinary filing period is two years and six months from the alleged act or omission, subject to applicable rules such as qualifying continuous treatment.

The statute’s special cancer-discovery provision concerns alleged negligent failure to diagnose cancer or a malignant tumor. It does not automatically extend the deadline for an allegation about prescribing or monitoring a cancer drug.

The date a complication was diagnosed therefore does not necessarily start a new filing period. Public defendants and death-related claims can involve additional requirements.

Under CPLR 3012-a, counsel bringing a medical malpractice action ordinarily provides a certificate concerning review of the facts and consultation with a knowledgeable physician. It is an attorney’s certification, subject to statutory alternatives and exceptions, rather than a physician-signed determination that malpractice has been proved.

Discuss a Possible PARP Inhibitor Treatment Error

If you believe important risks were misrepresented, treatment-selection information was overlooked or concerning laboratory results were not addressed, a legal review can examine the treatment decision, monitoring and resulting harm.

Contact Porter Law Group at 833-888-LATE, email info@porterlawteam.com, or request a free cancer treatment case evaluation.

You do not need a complete medical chart before making an inquiry. Continue medical care and discuss treatment questions with your oncology team independently of any legal consultation.

This article is for informational and educational purposes only. It is not a substitute for medical advice from a qualified healthcare provider or legal advice based on your specific circumstances.

Attorney Advertising. Reading this article or contacting Porter Law Group does not create an attorney-client relationship.

Frequently Asked Questions

Does longer progression-free survival mean I will live longer?

Not necessarily. Progression-free survival measures time until cancer progression or death, while overall survival measures time until death from any cause. A drug can improve PFS without demonstrating longer overall survival. Ask what both outcomes showed in the study most relevant to your cancer, biomarkers and treatment history.

Does a 70% reduction in progression risk mean 70% of patients are cured?

No. That wording usually describes a relative hazard reduction during study follow-up. It does not describe a cure rate or an absolute reduction of 70 percentage points. To understand the benefit, ask how many patients remained progression-free at a specific time and what happened in the comparison group.

Did SOLO1 definitively prove that olaparib improves overall survival?

The published seven-year analysis showed encouraging survival findings favoring olaparib, but it was descriptive and did not meet the trial’s prespecified statistical significance threshold. Its findings apply to newly diagnosed advanced ovarian cancer with a BRCA mutation after response to platinum chemotherapy. They should not be generalized to every ovarian cancer patient.

Can PARP inhibitor maintenance still be worthwhile without proven longer overall survival?

Yes, delaying progression may be valuable even when longer overall survival has not been demonstrated. The decision depends on the size of that benefit, applicable biomarkers, side effects, treatment burden and alternatives. A clear discussion should distinguish a demonstrated delay in progression from an unproven claim that treatment extends life.

Can a serious PARP inhibitor side effect support a malpractice claim?

Possibly, but a side effect alone does not establish negligence. A claim requires evidence of a departure from accepted care and resulting injury, or the separate requirements of an informed-consent claim. Relevant questions include whether treatment selection was appropriate, risks were adequately disclosed and abnormal monitoring results received an appropriate response.

Free case evaluation

Talk With a New York Cancer Lawyer

If a delayed diagnosis changed your family's future, Porter Law Group can review what happened and explain your options.